ANMOL ARORA

501904140
Q1 STRATEGY FORMULATION
SUBJECT: STRATEGIC MANAGEMENT
SUBMITTED TO: PROF. PADMAKUMAR NAIR

Indian pharmaceutical industry is known to be the world’s third largest medicine producer by volume
and the country's market manufactures around 60% of the vaccines globally. World Health
Organisation recognises India as the one of the leading contributors of the world pharmaceutical
market.

The Indian pharmaceutical industry supplies affordable and low-cost generic drugs and millions of
people around. The globe and is it contributor two more than 250 countries. The Indian
pharmaceutical industry has been working hard to combat the coronavirus. However, and The Indian
manufacturers rely heavily on call materials from China who is the top global producer.
Taking into account the supply chain disruptions and product export restrictions have led to
manpower job cuts and heavy in effect in this sector.

Detailed environmental Analysis of the Indian pharmaceutical industry will help understand more
about how companies can operate steadily and function with utmost efficiently at this time of
pandemic and maximise on its opportunities I'm minimising the threats that the pharmaceutical
industry is facing on global level.

The Indian pharmaceutical industry is known to maintain availability of large Labour and advanced
technologies that enable regulatory standards that are very high matching the USA and Europe.

As a Chief strategy officer of pharmaceutical company my first target would be

responding to the rapid changes arising in the supply chain and to change the business
processes. As there is a steep fall in the supply of active materials and ingredients from
China the biggest contributor to the Indian pharmaceutical industry for this I really
need to find alternatives in the manufacturing off medicines in my organisation and
find local resources to continue my active functions in order to cope up respond,
recover and thrive in this situation.

Taking due consideration upon the situation I will set up a crisis management team that will define
communication plans among the employees, customers and vendors. Such would be responsible
looking into the operations, people, information technology, regulatory, finance and industry.
Defining the scenario planning will trigger action and responsibility of each and every individual
concerned.

Inclusion of the team members from the critical functions and scheduling meetings or call on a
periodic basis and planning the continuity and recovery plans based on the various scenarios will be
the overall agenda in the long term of operation in the year 2020 -2021.

Before serving the Community drugs the target would be to ensure employee safety. I will set up
COVID HR team to monitor and track the employee while complying with administrative reporting
requirements. A strict protocol Will be set up for that staff working at plants and home with periodic
medical check-ups will be conducted on entry points with scanning and thermal check-ups.

Even though the company is working on cardiovascular and HIV\AIDS medicine a special task force
Will be established all the search and develop vaccine for the virus. In order to keep the supply
running the supply chain management team Will be given more apology and responsibilities keep on
the task running.
The manufacturing task force for the cardiovascular medicine would be divided in proper shifts and
timings in accordance with the government orders, it will then run 24 hours as there is a huge
dependency on the cardiovascular medicines manufactured my company.

Local resources will be found out with detailed study and analysis in order to maintain resources for
transport functioning in the manufacturing of the medicines.

Acquisitions, partnerships and mergers be established at national and local level in order to remain
functioning and operating all the time, as the supply chain will be the biggest hit department when it
really comes to lockdown and curfew so a special strategy will be established in the in order to cope
up the situation different plans will be made in order reach to the desired destination and supply of
the medicines in order to meet the demand from time to time so there is no shortage of supply to the
market.

STRENGTH:
 Strong hold in cardiovascular medicines market
 Strong brand presence across nation.
 Marketing and sales force.
 Manufacturing capacity.
WEAKNESSES:
 Stiff competition in generic medicines market.
 Limited presence in Europe and emerging market.
 Limited taskforce dur to lockdown.
 Falling availability of resources.
OPPORTUNITIES:
 Growing demand of medicines.
 Rising medical capacity due to coronavirus.
 Capitalisation opportunities in the general market.
 Rising value of pharmaceutical companies in India.
 Government relaxations and tariff support.
THREATS:
 Fall in raw material capacity from China.
 Supply chain disruption.
 Failing logistics support.
 Limited labour support.
 Sanitation and hygiene in times of Virus.
POLITICAL
RELAXATIONS ON
TAXES & TARRIFF.
STRINGENT PRICE
CONTROL
GOVT DEMAND
REGULATORY SOCIAL
STANDARDS
INC AGING
POPULATION &
IMMUNITY ISSUES AT
VIRUS.
FAILING AVAILABILITY
ECONOMIC IN DEMAND.
MORE PER CAPITA HOSPITAL & MEDICAL
HEALTH SPENDING. NEED & GROWTH
REDUCTION IN
CONSUMER
DISPOSABLE INCOME.
GLOBAL ECONOMIC
CRISIS.
MERGERS AND
ACQUISITIONS

TECHNOLOGICAL
ADVANCEMENT IN TECH
ROBOTIC ENGINEERING
BULK COPYING
NO IP POLICY
COMM TECH

ENVIRONMENTAL
PROACTIVE INNOVATIONS
GREEN MARKETING
CSR INTERLINKAGE
SOCIAL ADVERTISING
ENVIRONMENTAL
AGENDA

LEGAL
GLOBAL INCONSTANCIES
INCREASED LITIGATION
SANITATION
STANDARDS &
REGULATIONS
Major Environmental Concerns for the organisation remains:

1. The growing Japanese market and competition from China.

2. Risks from China linkages of supply of raw materials and API’s from them
3. Supply chain disruption in India.
4. Supply side disruptions due to labour participation.
5. Rising prices of drugs due to closures and lockdowns the commodities for production which
are cheap are not being imported hence higher costs of production is being incurred.
6. Inter State Transportation Challenges.

FORMAL STRATEGY:

Plant Operations:

 Prepare a roster of employees operating in the plant on a rotation basis,

keeping in mind risk assessment, location proximity, executive health
reports, annual check -up reports, and production- line requirements.

 Provide a production plan based on critical products to serve the market,

and focus on domestic market (as the export market may face dispatch
issues).

 Obtain police passes/letters for employees who have to travel and require
a transport vehicle and drivers.

 Ensure that the central PMO monitors deployment of people and staff.

Corporate Operations:

 Classify business activities as mission critical (critical activities that need to

be completed during lockdown) and others.

 Prepare and effectively communicate a detailed work chart for 30 days of

activities, roles, and responsibilities.
  Simplify processes to drive efficiencies and ensure people are redeployed.
For instance, HR/admin team can be retrained to perform certain PMO
tasks.

 Ensure that all payments and collection transactions are done

electronically, and that bank transfer details are collected and updated for
all electronic transfers.

Secure Access:

 Validate all ports exposed to the internet and remove unnecessary ports
for employees to work remotely and access the organisation’s network
and servers in a secure manner.
 Implement and enhance access restrictions on the allowed ports to
ensure there is no unauthorised access.

Review of the current inventory levels will be taken in order to see that what call materials are falling
short and what that required in the future and in order to improve the reliability and the visibility of
supplier’s communication with the alternate suppliers will be maintained.

The warehousing capacity will be increased for an indefinite period and disinfection in all other
departments and warehouses will be done from time to time.
Technical inventory will be stored of the key components required from time to time. If there is a
price increase alternate sourcing of supplies, additional cost, neutral logistics tariffs will be
maintained.

Alternate logistics partners for delivery will be contacted and approval from the appropriate authority
for the movement of essential goods in the event of Lockdown will be done and outbound logistics
options will be maintained.

Research & Development:

 Communicate with investigators to understand the specific issues COVID-

19 is creating at their sites (such as local lab testing capacity, patient
retention, serious adverse event risks).

 Investigate alternative timing or locations, and prioritise initiation of new

investigator sites in countries with a low potential risk.
  Establish strong patient communication plans.

 Establish an internal regulatory perspective on COVID-19 to guide

communications with institutional review boards and investigators.

 Understand from the regulators how to deal with enhanced event risk in
currently enrolled patients.

As the Indian government has announced and listed that some medicines are more essential than
the others our company really will focus on producing such essential medicines such as
paracetamol, bruffen , diclofenac, albendazole, azithromycin and proactive measures will be taken
in order to compete other companies in this domain of the pharmaceutical industry. There will be
widening of products and services provided by our company and we will maximise control over the
Pharmaceutical industry in this point of time as there is a high increase in demand of medicines in
every household where the other bidders are going possibility off in the scenario of the virus
expanding. Measures to strategize the year 2020-2021 and maximize the associated opportunities
involved will be taken into account.